 In a brief statement, Iovance Biotherapeutics Inc NASDAQ: IOVA company divulged that the FDA wants to see more data on the assays used to ensure each batch of its tumor-infiltrating lymphocyte therapy TIL is up to standard, in addition to what was already submitted. This FDA holdup pushed the submission of the lifileucel marketing application for melanoma in the first half of 2022, which amounts to a delay of more than a year from the original timeline of submitting in 2020. 